These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36380412)
1. Vaccines: An Important Tool for Infectious Disease. Saman S; Chauhan I; Srivastava N Recent Adv Antiinfect Drug Discov; 2023; 18(2):88-109. PubMed ID: 36380412 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in respiratory immunization: A focus on COVID-19 vaccines. He X; Chen X; Wang H; Du G; Sun X J Control Release; 2023 Mar; 355():655-674. PubMed ID: 36787821 [TBL] [Abstract][Full Text] [Related]
10. Chrysanthemum sporopollenin: A novel vaccine delivery system for nasal mucosal immunity. Liu J; Yan XD; Li XQ; Du YH; Zhu LL; Ye TT; Cao ZY; Dong ZW; Li ST; Xu X; Bai W; Li D; Zhang JW; Wang SJ; Li SH; Sun J; Yin XZ Front Immunol; 2023; 14():1132129. PubMed ID: 36845130 [TBL] [Abstract][Full Text] [Related]
11. Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z; Leong KW J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136 [TBL] [Abstract][Full Text] [Related]
12. Rational application of nanoadjuvant for mucosal vaccine delivery system. Dewangan HK J Immunol Methods; 2020; 481-482():112791. PubMed ID: 32387695 [TBL] [Abstract][Full Text] [Related]
13. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF mBio; 2021 Feb; 12(1):. PubMed ID: 33622722 [TBL] [Abstract][Full Text] [Related]
14. New-age vaccine adjuvants, their development, and future perspective. Verma SK; Mahajan P; Singh NK; Gupta A; Aggarwal R; Rappuoli R; Johri AK Front Immunol; 2023; 14():1043109. PubMed ID: 36911719 [TBL] [Abstract][Full Text] [Related]
15. Mucosal Vaccine Development Based on Liposome Technology. Bernasconi V; Norling K; Bally M; Höök F; Lycke NY J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of vaccine adjuvanticity at mucosal surfaces. Foss DL; Murtaugh MP Anim Health Res Rev; 2000 Jun; 1(1):3-24. PubMed ID: 11706842 [TBL] [Abstract][Full Text] [Related]
17. Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform. Ellison TJ; Talbott GC; Henderson DR Vaccine; 2023 Jan; 41(2):304-314. PubMed ID: 36587961 [TBL] [Abstract][Full Text] [Related]
18. Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination. Wang T; Wang N Curr Pharm Des; 2015; 21(36):5245-55. PubMed ID: 26412356 [TBL] [Abstract][Full Text] [Related]
19. The adjuvant effect of bacterium-like particles depends on the route of administration. Sudo H; Tokunoh N; Tsujii A; Kawashima S; Hayakawa Y; Fukushima H; Takahashi K; Koshizuka T; Inoue N Front Immunol; 2023; 14():1082273. PubMed ID: 36742329 [TBL] [Abstract][Full Text] [Related]